Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
LAE-001 by Laekna for Hormone-Sensitive Prostate Cancer: Likelihood of Approval
LAE-001 is under clinical development by Laekna and currently in Phase II for Hormone-Sensitive Prostate Cancer. According to GlobalData, Phase...
Data Insights
LAE-001 by Laekna for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
LAE-001 is under clinical development by Laekna and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...